Generation and Optimization of Off-The-Shelf Immunotherapeutics Targeting TCR-Vβ2+ T Cell Malignancy
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications